Dimerix Limited announced the appointment of Dr David Fuller as Chief Medical Officer. Dr Fuller is an internationally experienced pharmaceutical executive and physician with over 30 years' experience across pre-clinical and clinical development, as well as medical and regulatory affairs, and was the former CMO of Race Oncology. Dr Fuller, who has a strong fundamental background in the Dimerix technology having worked with Dimerix prior to public listing, will be responsible for the strategic delivery of the company's flagship ACTION3 Phase 3 clinical program for focal segmental glomerulosclerosis (FSGS) kidney disease currently recruiting globally.

His extensive experience and background across clinical trial, pharmacovigilance and regulatory strategy as a biopharmaceutical executive and physician will be instrumental as Dimerix continues to commercialise the asset. Dr Fuller has directly led a number of successful major market drug approvals, including Moraxen (UK), Busulfex (US Paediatrics and EU Adult indications), Xyrem (US) and Renagel (EU). He has also designed and executed multiple Phase I, II and III studies globally for both orphan and non-orphan drug products.Dr Fuller holds a Bachelor of Medicine /Bachelor of Surgery degree, and a Bachelor of Pharmacy (First Class Honours in Pharmacology), both from University of Sydney.

Dr Fuller also currently serves as Chairman for EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX- listed biotech company, AdAlta . Dr Fuller replaces outgoing CMO, Dr Ash Soman.